By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > Antipsychotic > Lurasidone

Lurasidone

GMJ
Last updated: 02/06/2026 14:30
By
Prof. Giorgi Pkhakadze
Share
5 Min Read
SHARE
3 min read|603 words

Lurasidone Drug Profile

What is Lurasidone?

Lurasidone is an atypical antipsychotic medication belonging to the benzisothiazol class of drugs. It is primarily prescribed to treat schizophrenia and certain types of bipolar disorder. The medication works by affecting neurotransmitter activity in the brain to help reduce symptoms of psychosis and mood episodes.

Uses

Lurasidone is FDA-approved for several psychiatric conditions:

  • Schizophrenia: Used to treat positive symptoms (hallucinations, delusions) and negative symptoms (social withdrawal, lack of motivation) in adults and adolescents aged 13-17
  • Bipolar I disorder depression: Treats depressive episodes in bipolar disorder, either as monotherapy or in combination with lithium or valproate
  • Bipolar depression in adolescents: Approved for treating bipolar depression in patients aged 10-17 years
  • Maintenance therapy: May be used for long-term management to prevent relapse of psychotic or mood episodes

How it works

Lurasidone works by blocking specific receptors in the brain, particularly dopamine D2 and serotonin 5-HT2A receptors. By modulating the activity of these neurotransmitters, it helps restore the chemical balance that becomes disrupted in conditions like schizophrenia and bipolar disorder. The medication also has activity at other serotonin receptors, which may contribute to its effectiveness in treating depression and reducing certain side effects.

Side effects

Common side effects include:

Submit Your Paper
GMJ_Submit_Banner
  • Nausea and vomiting
  • Drowsiness and sedation
  • Movement disorders (tremor, muscle stiffness)
  • Restlessness (akathisia)
  • Dizziness
  • Anxiety or agitation
  • Insomnia
  • Abdominal pain

Serious side effects to watch for:

  • Neuroleptic malignant syndrome (fever, muscle rigidity, altered mental status)
  • Tardive dyskinesia (involuntary repetitive movements)
  • Severe allergic reactions
  • Significant changes in blood sugar or cholesterol levels
  • Suicidal thoughts, especially in young adults

Warnings and precautions

  • Elderly patients with dementia: Increased risk of death; lurasidone is not approved for dementia-related psychosis
  • Pregnancy and breastfeeding: Should only be used when potential benefits outweigh risks; can cause withdrawal symptoms in newborns
  • Cardiovascular disease: May cause orthostatic hypotension and should be used cautiously in patients with heart conditions
  • Kidney or liver impairment: Dose adjustments may be necessary; severe hepatic impairment requires avoiding the medication
  • Seizure disorders: May lower seizure threshold; use with caution in patients with epilepsy or seizure history

Interactions

Lurasidone has several important drug interactions:

  • Strong CYP3A4 inhibitors (ketoconazole, clarithromycin): Can significantly increase lurasidone levels, potentially causing toxicity
  • Strong CYP3A4 inducers (rifampin, St. John’s wort): May reduce lurasidone effectiveness by lowering drug levels
  • Central nervous system depressants (alcohol, benzodiazepines): Enhanced sedation and respiratory depression risk
  • Antihypertensive medications: Increased risk of low blood pressure and dizziness
  • QT-prolonging drugs (certain antibiotics, antiarrhythmics): May increase risk of dangerous heart rhythm abnormalities
  • Grapefruit juice: Can increase lurasidone levels and should be avoided
  • Lithium: May increase risk of movement disorders when used together
  • Diabetes medications: Lurasidone may affect blood sugar control, requiring monitoring

Check interactions with the GMJ Interaction Checker

Dosage

Lurasidone dosing varies based on the condition being treated and individual patient factors. For schizophrenia in adults, the typical starting dose is 40 mg once daily, with a usual range of 40-80 mg daily and a maximum of 160 mg daily. For bipolar depression, doses typically range from 20-120 mg daily. The medication should be taken with food (at least 350 calories) to ensure proper absorption. Adolescent dosing is generally lower, starting at 20 mg daily. Dose adjustments may be necessary for patients with kidney impairment or when used with certain other medications. All dosing decisions should be individualized and determined by a qualified healthcare provider based on the patient’s specific medical condition and response to treatment.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Lurasidone." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/lurasidone/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
The 30-gram protein myth: why recent evidence challenges the fitness industry’s most durable claim

For over a decade, the fitness industry has promoted a rule: your…

How the gut absorbs nutrients with molecular precision: A seven-meter biochemical assembly line

The human gastrointestinal tract functions as a seven-meter nutrient-extraction assembly line, with…

Why Thiamine Deficiency Is Silent but Serious in Heart Failure Patients

Loop diuretics—the standard treatment for heart failure—deplete thiamine, the essential cofactor for…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Chlorpromazine

By
Prof. Giorgi Pkhakadze
02/06/2026

Aripiprazole

By
Prof. Giorgi Pkhakadze
02/06/2026

Clozapine

By
Prof. Giorgi Pkhakadze
02/06/2026

Olanzapine

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up